Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 3/20 | 0.37 |
| ▸ | ACE | P12821 | 3/20 | 0.37 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 5/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20126948 | 0.94 | NOD1 (0.38) | NOD1CCR2MMEACESLC6A5 | |
| SCHEMBL20100663 | 0.90 | ACE (0.43) | NOD1CCR2MMEACECPA1 | |
| SCHEMBL20100662 | 0.84 | ACE (0.38) | NOD1MMEACEMMP2MMP3 | |
| SCHEMBL20100656 | 0.83 | FOLH1 (0.43) | NOD1MMEACE | |
| SCHEMBL20126949 | 0.82 | MME (0.41) | NOD1MMEACEMMP2MMP3 | |
| SCHEMBL20126950 | 0.80 | NOD1 (0.38) | NOD1MMEACESLC6A5MMP2 | |
| SCHEMBL29604034 | 0.78 | AKR1C3 (0.46) | CCR2ACE2AKR1C3AKR1C2 | |
| SCHEMBL24796368 | 0.73 | NOD1 (0.73) | NOD1SLC6A5 | |
| SCHEMBL19273454 | 0.73 | NOD1 (0.73) | NOD1SLC6A5 | |
| SCHEMBL31017279 | 0.72 | EPHX1 (0.45) | CCR2AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767354-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-26 | — | — | US | disclosed |
| US-20180117170-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117170-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | NOD1 1373/4885CCR2 465/4885MME 432/4885 |
| US-11767354-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | NOD1 1373/4885CCR2 465/4885MME 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.